[b]I hate to advocate drugs, alcohol, violence, or insanity to anyone, but they've always worked for me.[/b]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jour, I also get your point, but for now NH is focused on the CNS basket.
Am sure there are things going on with the ADF platform, not so sure they will be disclosed unless it is something positive.
And the ADF was all over a labeling issue to begin with. There could have been an ADF out there 2 years ago. 163 person BE and no problems. None.
Like Purdue still gets to keep their OxyContin crap on the market. Abused and not even properly labeled. It is NOT a 12 hour ER. In many cases it doesn't even extend pain relief to 8 hours. This has been documented. Yet the FDA says that is okay, right?
Pay for play.....
newguy, I like your Accumulating Reserve. Nice~!
Call them.
What does WS stand for? Walmart Stores?
Not a bad guess Winechemist.
J G D, I just use the Every $50 million in revenue is going to be about $1
per share. that includes a PE of about 20.
Now factor in CNS Adderall IR, plus the pending $1.6 billion CNS drug where Elite/SunGen will likely start out with revenues that eventually ramp with each quarter.
Then there is the "wildcard" isradipine, which as per your post has unique possibilities for Elite/Glenmark.
I did not mention Elite's ADF once in this picture. Your post about says it
all J G D and you did not mention Elite's opioid ADFs either.
This has the potential to be a fun ride.
GLTA
Did I say this was about opioid ADFs? No I did not. My comment has nothing to do with Elite's opioid ADF platform.
Jour, who said I was referring to an ADF?
Try again.
Excellent post NASDAQ. Is the FDA paying attention? Nope.
Here's how it works:
PAY FOR PLAY.
Simple math will give a simple answer with a PE minimum multiple of 20.
newguy, the MMs are trying their best to keep a lid on it. They can do this so long as nothing pops up on the radar like the $1.6 billion ANDA approval. As posted, a date to look for is anytime after April 21st.
The FDA may be a little behind due to the unnecessary government shut down months ago. They will eventually catch up.
tedk10 awesome post. Well put ted. Keep everything in perspective, and as an investor all will be okay.
The SunGen Glenmark Lannett partnerships will be what launches Elite.
Elite's ADF is no longer the key here. Still viable, but not the key.
tedk10, you understand it.
good catch bulldog, and thanks for the FDA orange book information WeeZuhl.
Yes. As others try to buy cheap shares by keeping the price of those shares suppressed.
It's all bullshit 62bluejay. Love how the FDA skirts the real problem by creating other problems. Now they want to put a limit "taper" patients with new labels. But but but its just a labeling problem then, right?
WRONG! It's a quick fix to a problem they have no answer for at the moment.
Typical FDA response. Wonder how many of the FDA approved drugs have Tmax problems after a super heavy meal. Lots is my guess. The fix? A labeling fix is also my guess. Not Elite though.
NASDAQ, don't forget Percocet and Hydrocodone. Elite has already formulated their ADF into these APAPs, but the FDA in all of its wisdom said these formulations were already abuse proof due to Acetaminophen. Lawsuits against opioid manufacturers who manufacture Percocet and other APAPs prove the FDA had its head up its ass. They may need to think about this already tested ADF formulation Elite has in its portfolio of ADFs.
As another also posted some time ago, the quota given to Elite will be
sold completely. PH4RM4C3UT1C4LS is this so? TIA
N2K thank you for the compliment. From you it means a lot.
There are two situations I have seen where top executives get involved with their time and effort where they too must roll up their sleeves. One is where a situation like Elite happens. A company that is trying to maintain low cost to their bottom line while trying to build value in the company as a whole. The goal is simply to take a company that had almost nothing and make it into a company other companies would like to have as a part of their company. Elite's drug portfolio is going to be recognized and targeted by others. Elite has also made itself a company other companies would like to partner with, examples Glenmark, SunGen,
and Lannett.
Another situation is where the company tells its employees to make the effort or find another place to work. Am very familiar with that one.
I believe Elite is in the first scenario. Those executives that are not afraid to get involved with the work by doing a part of it I have a great deal of respect for. They are many times what drives the company over the top by being not just a mouthpiece, but an example. Employees often times rally behind a person like that. Hey, if I'm employed by Elite and see that buyout carrot hanging for my future I am likely to put in a little extra effort in seeing my dreams come true, and have incentive to get the stock price going up, especially if I see the top guy busting his stones as well.
No top executive left Elite over the weekend? Maybe the person was referring to the late nights folks are putting in at the facility when they mentioned a top executive left Elite over the weekend.
NASDAQ2020, looking forward to a possible wild card weekend.
Thanks for all of the DD.
The FDA won't take their time with this one or they look like baboons.
All the clout MJF has and all of the attention P D draws? Seriously....
the FDA takes their time and they will look like Jack Aces.
Thanks for clarifying that NASDAQ.
But I thought Purdue was going to be okay. Now you claim BK within weeks?
Guess those ~2000 lawsuits are impacting Purdue and the Sackler family. So sad.
Closetinvestor, share price hasn't changed, I will grant you that. The company's outlook has totally changed though. SunGen partnership is going to be a very good one for both companies. Glenmark and Lannett also very good for all parties concerned.
This company is not the same as it was back in 2015. Do your due diligence.
GLTY
The increase is more than likely as a BP medication. Just gaining traction in the market over time. This would also apply to Methadone and the others as well.
P D patients would have to wait until Isradipine is approved for P D/ hypertensive patients and can be prescribed as off label is my guess.
But as you have posted, revenues are growing with respect to the generics Elite has out there.
So Ama, you and I along with other longs are awaiting the $1.6 billion market ANDA approval. Got any guesses as to when? Sometime in April... but your estimate as to when in April.
TIA
Could it be Teva may partner with Elite on the ADFs?
Some roses don't smell.
JBDiver, I do not think that Isradipine results hanging in the balance are what is propelling the share price up. And I highly doubt negative results
will push Elite's share price down because that is already baked in. Not counting on these results as a windfall.
The main component to the share price right now are the CNS drugs Lannett is marketing and will be marketing/ selling for Elite. The $1.6 billion ANDA is awaiting approval and once approved will be marketed and sold by Lannett along with Adderall IR. That is what is currently propelling the stock price up IMHO.
Isradipine will be an unexpected windfall which will strengthen the already
strong chart.
Now we all know it~! LOL
Shhhhh it's supposed to be a secret.... hehehehehe
So what is driving the share price of Elite currently? Isradipine? Or is it a combination of things prior to any development concerning Isradipine as a treatment for P D?
IMO it is the developments which have transpired prior to any findings with Isradipine. Glenmark, then Lannett, marketing and sales of Adderall IR which is to start (or already has). The upcoming $1.6 billion dollar CNS drug ANDA also has to do with this share price movement IMO. To a degree methadone.
Isradipine will be concluded May7th. Then it will come into play. I believe the market move is waiting for the $1.6 billion ANDA approval.
Isradipine still has no impact on share price. Now that both sides have been presented, if Isradipine findings are not positive for P D it is my opinion that the share price for such a finding is already baked in. If the findings for Isradipine are positive they will add strength to the current stock price movement.
Yes, the FDA is a total JOKE. I see it every single day. Bought and paid for. Told to look the other way. Less regulations... just keep those drug prices cheap for those that are willing to pay.
Every day Nammy, I see it every single day.